Tools
Stock profile

Protagonist Therapeutics, Inc (PTGX)

PTGX · Latest close $127.16 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$127.16
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
4
vs previous quarter

Protagonist Therapeutics, Inc (PTGX) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 4 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $26.9M sold). Latest close $127.16 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-26.9M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

RTW Investments · Perceptive Advisors · OrbiMed Advisors — 5 tracked funds hold PTGX. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 6 sales ($26.9M). Insider trading

Often held alongside

PTC THERAPEUTICS, INC. (PTCT) · Travere Therapeutics, Inc. (TVTX) · UroGen Pharma Ltd. (URGN) · Guardant Health, Inc. (GH) · Abivax S.A. (ABVX) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
RTW Investments5.30%5,061,175HELD Q3 filed Nov 16
Perceptive Advisors1.81%981,879TRIMMED (-20.2%) Q3 filed Nov 16
OrbiMed Advisors0.10%42,100HELD Q3 filed Nov 16
Axiom Investors0.09%81,683TRIMMED (-4.4%) Q3 filed Nov 12
Polen Capital Management0.02%22,651TRIMMED (-6.9%) Q3 filed Nov 13
Rubric Capital Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -0.4% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

158.6230.152024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding344 of 8,857 filers
Long-only filers among them342
Change vs 2026 Q1+23 net · 330 entered · 307 exited
Shares reported, all filers75,780,384
Reported value, all filers$9.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$46.0M
Net income · FY2025$-130.1M
Total assets · FY2025$668.2M
Shares outstanding64,708,285
Market cap (at latest close)$8.2B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 202610,297,224
Share of shares outstanding15.91%
Days to cover12.02

Shares short at recent settlements — Jul 31, 2026: 7.5M · Aug 14, 2026: 7.8M · Aug 31, 2026: 7.7M · Sep 15, 2026: 8.1M · Sep 30, 2026: 9.3M · Oct 15, 2026: 10.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 3K · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 6 sales by 3 insiders ($26.9M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 16, 2026MOLINA ARTURO MDChief Medical OfficerSell2,718$124.65$338.8KSEC filing
Sep 30, 2026Ali AsifChief Financial OfficerSell12,595$141.77$1.8MSEC filing
Sep 30, 2026Ali AsifChief Financial OfficerSell46,034$141.78$6.5MSEC filing
Sep 10, 2026PATEL DINESH V PH DPresident and CEOSell7,278$144.10$1.0MSEC filing
Sep 9, 2026PATEL DINESH V PH DPresident and CEOSell63,548$146.18$9.3MSEC filing
Sep 8, 2026PATEL DINESH V PH DPresident and CEOSell54,174$145.87$7.9MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 30, 2026ASIF ALIOfficer58,629$8.3MSep 30, 2026SEC filing
Aug 10, 2026Dinesh PatelCEO225,000$33.6MAug 10, 2026SEC filing
Jun 23, 2026WILLIAM WADDILLDirector9,000$1.0MJun 23, 2026SEC filing
Jun 10, 2026WILLIAM WADDILLDirector9,000$952.8KJun 10, 2026SEC filing
May 29, 2026WILLIAM WADDILLDirector9,000$903.7KMay 29, 2026SEC filing
May 12, 2026Dinesh PatelCEO75,000$7.8MMay 12, 2026SEC filing
May 8, 2026BRYAN M & COURTNEY L GIRAUDO RTDirector11,130$1.1MMay 8, 2026SEC filing
May 7, 2026BRYAN GIRAUDODirector36,000$3.6MMay 7, 2026SEC filing
May 7, 2026BRYAN M & COURTNEY L GIRAUDO RTDirector12,000$1.2MMay 7, 2026SEC filing
Apr 21, 2026Asif AliOfficer1,750$184.6KApr 20, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 13, 2026Farallon Capital Management, L.L.C.SC 13G/A6,433,11910.0%Jun 30, 2026SEC filing
Aug 7, 2026STATE STREET CORPORATIONSC 13G3,321,5545.2%Jun 30, 2026SEC filing
May 12, 2026STATE STREET CORPORATIONSC 13G3,116,8044.9%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G3,250,0035.1%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Portfolio ManagementSC 13G3,533,0155.5%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026RTW Investments, LPSC 13G/A5,059,0538.1%Dec 31, 2025SEC filing
Feb 10, 2026Wellington Management Group LLPSC 13G3,171,4235.1%Dec 31, 2025SEC filing
Feb 6, 2026Farallon Capital Partners, L.P.SC 13G/A283,0620.5%Dec 31, 2025SEC filing
Jan 30, 2026The Vanguard GroupSC 13G/A5,413,6908.7%Dec 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold PTGX — ranked by lift, the co-holding pattern described in Methodology: PTC THERAPEUTICS, INC. (PTCT) · Travere Therapeutics, Inc. (TVTX) · UroGen Pharma Ltd. (URGN) · Guardant Health, Inc. (GH) · Abivax S.A. (ABVX) · COGENT BIOSCIENCES INC (COGT) · Praxis Precision Medicines, Inc. (PRAX) · RHYTHM PHARMACEUTICALS INC (RYTM).

Recent 8-K filings

FiledItemsSource
Nov 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 5, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Jun 18, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

PTC THERAPEUTICS, INC. (PTCT) · Track Record: how the signals scored · Practice timing on PTGX

One email a week: the week’s new filings and research. Subscribe free

← PTEN  ·  PTLO →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.